Skip to main content
Premium Trial:

Request an Annual Quote

Human Genome Sciences Opens Genomics Drug Plant

Premium

ROCKVILLE, Md.--Human Genome Sciences opened a $42 million plant here this month, where it said it will manufacture drugs resulting from genomics research and development. Calling his company the "world's genomics pioneer," William Haseltine, CEO of Human Genome Sciences, said, "HGS was the first group anywhere to sequence most of the genes in the human genome. HGS was also the first company to place three genomics-derived drugs into human clinical trials." He added, "Our hope is that HGS will be the first company to manufacture and market genomics-derived drugs."

The plant is situated on Johns Hopkins University's Belward Research Campus, a 138-acre tract to be developed by the university to focus on research and development laboratories, associated office space, government agencies, and healthcare delivery facilities. Construction by Human Genome Sciences is already underway on a 40,000-square-foot expansion shell to house an additional production line adjacent to the new 80,000-square-foot manufacturing and process development plant.

Filed under

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.